Rinvoq (Upadacitinib)

upadacitinib 30 mg modified release tablet, 28 · ORAL · PBS code 13762H

AUTHORITY_REQUIRED

What it costs

AU$1820.79 PBS-determined price per 28 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2023-12-01.
• Repeats: 2.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe Crohn disease

Extended induction period (optional) from weeks 12 to 24

Patient must must have experienced an inadequate therapeutic benefit following the initial 12-week induction period; AND

Must be treated by a gastroenterologist; or

Must be treated by a consultant physician [internal medicine specialising in gastroenterology]; or

Must be treated by a consultant physician [general medicine specialising in gastroenterology]; AND

Patient must be at least 18 years of age.

Sponsor: AbbVie Pty Ltd ABN 48 156 384 262

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.